inobrodib (CCS1477)
Multiple Myeloma
Phase 1/2Active
Key Facts
About CellCentric
CellCentric is a UK-based, private biotech founded in 2004, focused on inhibiting the epigenetic targets p300 and CBP for oncology. Its lead candidate, inobrodib, is a first-in-class, oral small molecule currently in clinical trials for multiple myeloma, with promise in other cancers. The company emphasizes a collaborative R&D model and aims to deliver a convenient, community-based treatment option to improve patient access and quality of life. CellCentric is led by an experienced team of drug developers and is backed by investor directors on its board.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |
| Sequesta™ | ID4Pharma | Pre-clinical |